FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Harriet Kluger

Research Profile

Disorders

Procedures

Chemicals & Drugs

Anatomy

Tumor Cell Line

Concepts & Ideas

Devices

Physiology

Gene Expression Regulation, Neoplastic

Phenomena

Blotting, Western

Co-author Network

Publications

TOP 3
Jaclyn C Flanigan; Lucia B Jilaveanu; Veronica L Chiang; Harriet M Kluger
Advances in therapy for melanoma brain metastases.
Joshua A Sznol; Lucia B Jilaveanu; Harriet M Kluger
Studies of NVP-BEZ235 in melanoma.
G T Gibney; W K Kelly; B E Schwartz; S A Aziz; R L Camp; C R Chen; P Conrad; Harriet M Kluger
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Harriet Kluger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Jaclyn C Flanigan; Lucia B Jilaveanu; Veronica L Chiang; Harriet M Kluger
Advances in therapy for melanoma brain metastases.
Clinics in dermatology 2013;31(3):264-81.
2013: Joshua A Sznol; Lucia B Jilaveanu; Harriet M Kluger
Studies of NVP-BEZ235 in melanoma.
Current cancer drug targets 2013;13(2):165-74.
2013: G T Gibney; W K Kelly; B E Schwartz; S A Aziz; R L Camp; C R Chen; P Conrad; Harriet M Kluger
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(2):343-9.
2013: Saadia A Aziz; Robert L Camp; Yuval Kluger; Fabio Parisi; Joshua A Sznol; Adebowale Adeniran; Harriet M Kluger
Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors.
BMC clinical pathology 2013;13():3.
2013: Saadia A Aziz; Robert L Camp; John W Colberg; Adebowale Adeniran; Joshua Sznol; Harriet M Kluger
Vascularity of primary and metastatic renal cell carcinoma specimens.
Journal of translational medicine 2013;11():15.
2012: Janice M Mehnert; Harriet M Kluger
Driver mutations in melanoma: lessons learned from bench-to-bedside studies.
Current oncology reports 2012;14(5):449-57.
2012: Fabio Parisi; Francesco Strino; Fang Xu; Peining Li; Mariann Micsinai; Deepak Narayan; Stephan Ariyan; Antonella Bacchiocchi; Elaine Cheng; Ruth Halaban; Harriet M Kluger; Yuval Kluger
Integrated analysis of tumor samples sheds light on tumor heterogeneity.
The Yale journal of biology and medicine 2012;85(3):347-61.
2012: Michael Krauthammer; Richard P Lifton; Roger S Lo; Shuangge Ma; Shrikant M Mane; Miguel A Materin; James P McCusker; Deepak Narayan; Joseph Schlessinger; David F Stern; Mario Sznol; Stephan Ariyan; Antonella Bacchiocchi; Titus J Boggon; Marcus W Bosenberg; Douglas E Brash; Ana Capatana; Elaine Cheng; Murim Choi; Matthew J Davis; Ken Dutton-Regester; Perry Evans; Gerald Goh; Byung Hak Ha; Nicholas K Hayward; Edna C Holman; Kenneth K Kidd; Harriet M Kluger; Yong Kong; Ruth Halaban
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Nature genetics 2012;44(9):1006-14.
2012: Lucia B Jilaveanu; Harriet M Kluger; Joshua Sznol; Saadia A Aziz; Dylan Duchen; Robert L Camp
CD70 expression patterns in renal cell carcinoma.
Human pathology 2012;43(9):1394-9.
2012: Jonathan P S Knisely; Mario Sznol; James B Yu; Jaclyn Flanigan; Harriet M Kluger; Veronica L S Chiang
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.
Journal of neurosurgery 2012;117(2):227-33.
2012: Christopher R Zito; Harriet M Kluger
Immunotherapy for metastatic melanoma.
Journal of cellular biochemistry 2012;113(3):725-34.
2012: Jaykumar Thumar; Eva Giesen; Harriet M Kluger
Drug targets and predictive biomarkers in the management of metastatic melanoma.
Pharmacogenomics and personalized medicine 2012;5():139-48.
2012: David Shahbazian; Joshua Sznol; Harriet M Kluger
Vertical pathway targeting in cancer therapy.
Advances in pharmacology (San Diego, Calif.) 2012;65():1-26.
2012: Christopher R Zito; Valsamo Anagnostou; Gerold Bepler; Robert Camp; Wolfgang Hackl; Lucia B Jilaveanu; Harriet M Kluger; Sauveur-Michel Maira; David Rimm; Herta H Chao
Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells.
PloS one 2012;7(2):e31331.
2011: Matthew M Burke; Marjorie Golden; Kevin N Heller; Axel Hoos; Harriet M Kluger; Mario Sznol
Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(32):e792-4.
2011: Miguel A Materin; Mark Faries; Harriet M Kluger
Molecular alternations in uveal melanoma.
Current problems in cancer 2011;35(4):211-24.
2011: Jaclyn C Flanigan; Lucia B Jilaveanu; Stephan Ariyan; Veronica L Chiang; Mark Faries; Jonathan P S Knisely; Mario Sznol; James B Yu; Harriet M Kluger
Melanoma brain metastases: is it time to reassess the bias?
Current problems in cancer 2011;35(4):200-10.
2011: Harriet M Kluger; Arkadiuz Z Dudek; Carrie McCann; Jean Ritacco; Nadine Southard; Lucia B Jilaveanu; Annette Molinaro; Mario Sznol
A phase 2 trial of dasatinib in advanced melanoma.
Cancer 2011;117(10):2202-8.
2011: Harriet M Kluger; Kathleen Hoyt; Antonella Bacchiocchi; Tina Mayer; Jonathan Kirsch; Yuval Kluger; Mario Sznol; Stephan Ariyan; Annette Molinaro; Ruth Halaban
Plasma markers for identifying patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(8):2417-25.
2011: Lucia B Jilaveanu; Christopher R Zito; Saadia A Aziz; Ashok Chakraborty; Michael A Davies; Robert L Camp; David L Rimm; Arkadiusz Dudek; Mario Sznol; Harriet M Kluger
In vitro studies of dasatinib, its targets and predictors of sensitivity.
Pigment cell & melanoma research 2011;24(2):386-9.
2011: Aymen A Elfiky; Wolfgang Hackl; Saadia A Aziz; Patricia J Conrad; Michel Maira; Camp L Robert; Summar Siddiqui; Harriet M Kluger
Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer.
Journal of translational medicine 2011;9():133.
2010: Saadia A Aziz; Lucia B Jilaveanu; Christopher Zito; Robert L Camp; David L Rimm; Patricia Conrad; Harriet M Kluger
Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(24):6029-39.
2010: Jaykumar R Thumar; Harriet M Kluger
Ipilimumab: a promising immunotherapy for melanoma.
Oncology (Williston Park, N.Y.) 2010;24(14):1280-8.
2010: Amnon Golan; Elah Pick; Lyuben Tsvetkov; Yasmine Nadler; Harriet M Kluger; David F Stern
Centrosomal Chk2 in DNA damage responses and cell cycle progression.
Cell cycle (Georgetown, Tex.) 2010;9(13):2647-56.
2010: Janice M Mehnert; Mary M McCarthy; Lucia Jilaveanu; Keith T Flaherty; Saadia Aziz; Robert L Camp; David L Rimm; Harriet M Kluger
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays.
Human pathology 2010;41(3):375-84.
2010: Y Nadler; A M González; Robert L Camp; David L Rimm; Harriet M Kluger; Yuval Kluger
Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(3):466-73.
2010: Fabio Parisi; David L Rimm; Yasmine Nadler; Robert L Camp; Ana M Gonzalez; Harriet M Kluger; Yuval Kluger
Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models.
Breast cancer research : BCR 2010;12(5):R66.
2010: Jill C Rubinstein; Mario Sznol; Anna C Pavlick; Stephan Ariyan; Elaine Cheng; Antonella Bacchiocchi; Harriet M Kluger; Deepak Narayan; Ruth Halaban
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.
Journal of translational medicine 2010;8():67.
2009: Bonnie E Gould Rothberg; Aaron J Berger; Annette M Molinaro; Antonio Subtil; Michael O Krauthammer; Robert L Camp; William R Bradley; Stephan Ariyan; Harriet M Kluger; David L Rimm
Melanoma prognostic model using tissue microarrays and genetic algorithms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(34):5772-80.
2009: Lucia B Jilaveanu; Saadia A Aziz; Harriet M Kluger
Chemotherapy and biologic therapies for melanoma: do they work?
Clinics in dermatology 2009;27(6):614-25.
2009: Lucia B Jilaveanu; Christopher R Zito; Saadia A Aziz; Patricia J Conrad; John C Schmitz; Mario Sznol; Robert L Camp; David L Rimm; Harriet M Kluger
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(18):5704-13.
2009: Saadia A Aziz; Michael Davies; Elah Pick; Christopher Zito; Lucia Jilaveanu; Robert L Camp; David L Rimm; Yuval Kluger; Harriet M Kluger
Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3029-36.
2009: Ho-Hyung Woo; Y Zhou; X Yi; Cynthia L David; Wenxin Zheng; Maureen Gilmore-Hebert; Harriet M Kluger; E Cagnur Ulukus; T Baker; J B Stoffer; Setsuko K Chambers
Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer.
Oncogene 2009;28(9):1176-86.
2009: Lucia Jilaveanu; Christopher Zito; Sandra J Lee; Katherine L Nathanson; Robert L Camp; David L Rimm; Keith T Flaherty; Harriet M Kluger
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(3):1076-85.
2008: Ernest C Borden; Harriet M Kluger; John Crowley
Apoptosis: a clinical perspective.
Nature reviews. Drug discovery 2008;7(12):959.
2008: Harriet M Kluger; Summar F Siddiqui; Cesar Angeletti; Mario Sznol; William K Kelly; Annette M Molinaro; Robert L Camp
Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells.
Laboratory investigation; a journal of technical methods and pathology 2008;88(9):962-72.
2008: Bonnie E Gould Rothberg; Christopher B Moeder; Harriet M Kluger; Ruth Halaban; David E Elder; George F Murphy; Alexander Lazar; Victor Prieto; Lynn McDivitt Duncan; David L Rimm
Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2008;21(9):1121-9.
2008: Yasmine Nadler; Robert L Camp; Candice Schwartz; David L Rimm; Harriet M Kluger; Yuval Kluger
Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4455-62.
2008: Nicolas Acquavella; Harriet M Kluger; John Rhee; Leonard Farber; Harold Tara; Stephan Ariyan; Deepak Narayan; William Kelly; Mario Sznol
Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(6):569-76.
2008: Mary M McCarthy; Elah Pick; Yuval Kluger; B Gould-Rothberg; Rossitza Lazova; Robert L Camp; David L Rimm; Harriet M Kluger
HSP90 as a marker of progression in melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):590-4.
2008: Anindita Bhoumik; Boris Fichtman; Charles Derossi; Wolfgang Breitwieser; Harriet M Kluger; Sean Davis; Antonio Subtil; Paul Meltzer; Stan Krajewski; Nic Jones; Ze'ev Ronai
Suppressor role of activating transcription factor 2 (ATF2) in skin cancer.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(5):1674-9.
2008: Yasmine Nadler; Robert L Camp; Jennifer Giltnane; Christopher Moeder; David L Rimm; Harriet M Kluger; Yuval Kluger
Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.
Breast cancer research : BCR 2008;10(2):R35.
2008: Elah Pick; Mary M McCarthy; Harriet M Kluger
Assessing expression of apoptotic markers using large cohort tissue microarrays.
Methods in molecular biology (Clifton, N.J.) 2008;414():83-93.
2007: Kenneth Bromberg; Harriet M Kluger; Agnes Delaunay; Sabiha Abbas; Kyle A DiVito; Stan Krajewski; Ze'ev Ronai
Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer.
Cancer research 2007;67(17):8172-9.
2007: Elah Pick; Yuval Kluger; Jennifer Giltnane; Christopher Moeder; Robert L Camp; David L Rimm; Harriet M Kluger
High HSP90 expression is associated with decreased survival in breast cancer.
Cancer research 2007;67(7):2932-7.
2007: Harriet M Kluger; Mary M McCarthy; Ayesha B Alvero; Mario Sznol; Stephan Ariyan; Robert L Camp; David L Rimm; Gil Mor
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization.
Journal of translational medicine 2007;5():6.
2006: Elaine Cheng; Sergio E Trombetta; Daniela Kovacs; Robert Beech; Stephan Ariyan; Miguel Reyes-Mugica; Jennifer M McNiff; Deepak Narayan; Harriet M Kluger; Mauro Picardo; Ruth Halaban
Rab33A: characterization, expression, and suppression by epigenetic modification.
The Journal of investigative dermatology 2006;126(10):2257-71.
2006: Mary M McCarthy; Kyle A DiVito; Mario Sznol; Daniela Kovacs; Ruth Halaban; Aaron J Berger; Keith T Flaherty; Robert L Camp; Rossitza Lazova; David L Rimm; Harriet M Kluger
Expression of tumor necrosis factor--related apoptosis-inducing ligand receptors 1 and 2 in melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(12):3856-63.
2006: Vanita Noronha; Dennis L Cooper; Susan A Higgins; John R Murren; Harriet M Kluger
Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel.
The lancet oncology 2006;7(3):270-1.
2006: Yuval Kluger; Harriet M Kluger; David Tuck
Association between pathways in regulatory networks.
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference 2006;1():2036-40.
2006: David Tuck; Harriet M Kluger; Yuval Kluger
Characterizing disease states from topological properties of transcriptional regulatory networks.
BMC bioinformatics 2006;7():236.
2005: Mary M McCarthy; Mario Sznol; Kyle A DiVito; Robert L Camp; David L Rimm; Harriet M Kluger
Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(14):5188-94.
2005: Harriet M Kluger; Dina Chelouche Lev; Yuval Kluger; Mary M McCarthy; Galina Kiriakova; Robert L Camp; David L Rimm; Janet E Price
Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.
Cancer research 2005;65(13):5578-87.
2005: Malini Harigopal; Aaron J Berger; Robert L Camp; David L Rimm; Harriet M Kluger
Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4083-9.
2004: Kyle A DiVito; Aaron J Berger; Robert L Camp; Marisa Dolled-Filhart; David L Rimm; Harriet M Kluger
Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma.
Cancer research 2004;64(23):8773-7.
2004: Aaron J Berger; Robert L Camp; Kyle A DiVito; Harriet M Kluger; Ruth Halaban; David L Rimm
Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome.
Cancer research 2004;64(23):8767-72.
2004: Keith Hoek; David L Rimm; Kenneth R Williams; Hongyu Zhao; Stephan Ariyan; Aiping Lin; Harriet M Kluger; Aaron J Berger; Elaine Cheng; Eduardo S. Trombetta; Terence Wu; Michio Niinobe; Kazuaki Yoshikawa; Gregory E Hannigan; Ruth Halaban
Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas.
Cancer research 2004;64(15):5270-82.
2004: Dina Chelouche Lev; Harriet M Kluger; Aaron J Berger; David L Rimm; Janet E Price
alphaB-crystallin as a marker of lymph node involvement in breast carcinoma.
Cancer 2004;100(12):2543-8.
2004: Harriet M Kluger; Kyle A DiVito; Aaron J Berger; Ruth Halaban; Stephan Ariyan; Robert L Camp; David L Rimm
Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study.
Melanoma research 2004;14(3):207-10.
2004: Harriet M Kluger; Yuval Kluger; Maureen Gilmore-Hebert; Kyle A DiVito; Joseph T Chang; Sofya Rodov; Olga Mironenko; Barry M Kacinski; Archibald S Perkins; Eva Sapi
cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model.
Laboratory investigation; a journal of technical methods and pathology 2004;84(3):320-31.
2004: Harriet M Kluger; Marisa Dolled-Filhart; Sofya Rodov; Barry M Kacinski; Robert L Camp; David L Rimm
Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):173-7.
2003: Aaron J Berger; Harriet M Kluger; Ning Li; Eric Kielhorn; Ruth Halaban; Ze'ev Ronai; David L Rimm
Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival.
Cancer research 2003;63(23):8103-7.